Cardiovascular Risk Reduction in Atrial Fibrillation Trial - Trial NCT04347330
Access comprehensive clinical trial information for NCT04347330 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Anzhen Hospital and is currently Recruiting. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 6000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Anzhen Hospital
Timeline & Enrollment
N/A
Aug 31, 2020
Aug 01, 2025
Primary Outcome
Composite cardiovascular outcomes
Summary
Atrial fibrillation (AF) is a serious public health problem because of its increasing
 incidence and prevalence in the aging population. AF is associated with elevated risks of
 death, stroke, coronary event, heart failure, cognitive decline, and chronic kidney disease.
 To identify preventive interventions for major cardiovascular events beyond effective
 anticoagulation should be a major priority in the treatment of AF patients. The CRAFT study
 is a 2-arm, multicenter, randomized clinical trial designed to test whether intensive blood
 pressure control will reduce the risk of major cardiovascular events in AF patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04347330
Non-Device Trial